Researchers have published evidence indicating that Cobenfy, a new drug for schizophrenia approved by the FDA in September 2024, may help reduce cognitive impairments in some patients, in addition to…
Read More
When someone develops mild cognitive impairment (MCI), is there a way of predicting whether that individual will go on to develop dementia?New research sheds important new light on the question.
Read More
In older adults, there is a well-established association between cognitive decline and depression and anxiety. Yet, as of now, “there are no evidence-based interventions for older adults that target…
Read More
An important study led by BBRF grantees has closely examined a commonplace pharmacologic property of many antipsychotic and other medications commonly prescribed to people with chronic schizophrenia…
Read More
Adding the drug guanfacine to a proven therapy program to treat cognitive deficits led to even better results for individuals with schizotypal personality disorder, say researchers who have just…
Read More
